AP2015008231A0 - Alkoxy pyrazoles as soluble guanylate cyclase activators - Google Patents

Alkoxy pyrazoles as soluble guanylate cyclase activators

Info

Publication number
AP2015008231A0
AP2015008231A0 AP2015008231A AP2015008231A AP2015008231A0 AP 2015008231 A0 AP2015008231 A0 AP 2015008231A0 AP 2015008231 A AP2015008231 A AP 2015008231A AP 2015008231 A AP2015008231 A AP 2015008231A AP 2015008231 A0 AP2015008231 A0 AP 2015008231A0
Authority
AP
ARIPO
Prior art keywords
guanylate cyclase
soluble guanylate
cyclase activators
pyrazoles
alkoxy
Prior art date
Application number
AP2015008231A
Other languages
English (en)
Inventor
John David Ginn
Jehrod Burnett Brenneman
Michael D Lowe
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AP2015008231A0 publication Critical patent/AP2015008231A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
AP2015008231A 2012-09-07 2013-09-03 Alkoxy pyrazoles as soluble guanylate cyclase activators AP2015008231A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261697899P 2012-09-07 2012-09-07
PCT/US2013/057826 WO2014039434A1 (fr) 2012-09-07 2013-09-03 Alcoxypyrazoles comme activateurs de guanylate cyclase soluble

Publications (1)

Publication Number Publication Date
AP2015008231A0 true AP2015008231A0 (en) 2015-01-31

Family

ID=49170904

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2015008231A AP2015008231A0 (en) 2012-09-07 2013-09-03 Alkoxy pyrazoles as soluble guanylate cyclase activators

Country Status (38)

Country Link
US (2) US8906904B2 (fr)
EP (1) EP2892891B1 (fr)
JP (1) JP5970134B2 (fr)
KR (1) KR101692707B1 (fr)
CN (1) CN104619695B (fr)
AP (1) AP2015008231A0 (fr)
AR (1) AR092869A1 (fr)
AU (1) AU2013312931B2 (fr)
BR (1) BR112015004529B1 (fr)
CA (1) CA2880494C (fr)
CL (2) CL2015000255A1 (fr)
CY (1) CY1122610T1 (fr)
DK (1) DK2892891T3 (fr)
EA (1) EA027244B1 (fr)
EC (1) ECSP15012804A (fr)
ES (1) ES2748798T3 (fr)
GE (1) GEP20176631B (fr)
HK (1) HK1210164A1 (fr)
HR (1) HRP20191755T1 (fr)
HU (1) HUE046996T2 (fr)
IL (1) IL236987A (fr)
LT (1) LT2892891T (fr)
MA (1) MA37891B1 (fr)
MD (1) MD4425C1 (fr)
MX (1) MX338887B (fr)
NZ (1) NZ703989A (fr)
PE (1) PE20151001A1 (fr)
PH (1) PH12015500457A1 (fr)
PL (1) PL2892891T3 (fr)
PT (1) PT2892891T (fr)
RS (1) RS59394B1 (fr)
SG (2) SG11201500861QA (fr)
SI (1) SI2892891T1 (fr)
TN (1) TN2015000054A1 (fr)
TW (1) TWI586661B (fr)
UA (1) UA115881C2 (fr)
UY (1) UY35012A (fr)
WO (1) WO2014039434A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2892891T (pt) * 2012-09-07 2019-11-05 Boehringer Ingelheim Int Alcoxi pirazoles como ativadores de guanilato ciclase solúvel
TW201625584A (zh) 2014-07-02 2016-07-16 諾華公司 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
AR101265A1 (es) 2014-07-22 2016-12-07 Boehringer Ingelheim Int Ácidos carboxílicos heterocíclicos como activadores de guanilato ciclasa soluble
KR20180095594A (ko) 2015-12-18 2018-08-27 노파르티스 아게 인단 유도체 및 가용성 구아닐레이트 시클라제 활성화제로서의 그의 용도
WO2018069148A1 (fr) 2016-10-11 2018-04-19 Bayer Pharma Aktiengesellschaft Combinaison contenant des activateurs gcs et des antagonistes du récepteur des minéralocorticoïdes
WO2019081456A1 (fr) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft Utilisation d'activateurs et de stimulateurs de sgc comprenant une sous-unité bêta2
EP3498298A1 (fr) 2017-12-15 2019-06-19 Bayer AG Utilisation de stimulateurs sgc et d'activateurs sgc seuls ou en combinaison avec des inhibiteurs pde5 pour le traitement de troubles osseux, y compris l'ostéogénèse imparfaite (oi)
EP3787610A1 (fr) 2018-04-30 2021-03-10 Bayer Aktiengesellschaft Utilisation d'activateurs de la gcs et de stimulateurs de la gcs pour le traitement de déficiences cognitives
EA202092680A1 (ru) 2018-05-15 2021-04-13 Байер Акциенгезельшафт 1,3-тиазол-2-ил-замещенные бензамиды для лечения заболеваний, ассоциированных с сенситизацией нервных волокон
EP3574905A1 (fr) 2018-05-30 2019-12-04 Adverio Pharma GmbH Procédé d'identification d'un sous-groupe de patients souffrant de dcssc qui bénéficie d'un traitement comportant des stimulateurs sgc et des activateurs sgc à un degré supérieur à celui d'un groupe de contrôle
JP2021530488A (ja) 2018-07-12 2021-11-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性グアニル酸シクラーゼ活性化薬としてのアルコキシピラゾール
US20220128561A1 (en) 2019-01-17 2022-04-28 Bayer Aktiengesellschaft Methods to determine whether a subject is suitable of being treated with an agonist of soluble gyanylyl cyclase (sgc)
CN112079712B (zh) * 2020-09-18 2022-12-13 江苏美迪克化学品有限公司 一种对乙烯基水杨酸的制备方法
GB202102895D0 (en) 2021-03-01 2021-04-14 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
US20230293513A1 (en) 2022-03-21 2023-09-21 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators for treating portal hypertension
WO2023237577A1 (fr) 2022-06-09 2023-12-14 Bayer Aktiengesellschaft Activateurs de guanylate cyclase soluble destinés à être utilisés dans le traitement de l'insuffisance cardiaque à fraction d'éjection préservée chez les femmes

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9824310D0 (en) * 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
WO2002026712A2 (fr) 2000-09-29 2002-04-04 Millennium Pharmaceuticals, Inc. Amines quaternaires et inhibiteurs du facteur xa associes
CN1568564A (zh) 2000-11-22 2005-01-19 维思克斯公司 用于非线性光学元件的温度启动的定位设备
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
GB0212785D0 (en) * 2002-05-31 2002-07-10 Glaxo Group Ltd Compounds
JP2006514043A (ja) 2002-12-20 2006-04-27 ファルマシア・コーポレーション マイトジェン活性化タンパク質キナーゼ−活性化タンパク質キナーゼ−２を阻害する化合物
US20100016305A1 (en) 2005-07-18 2010-01-21 Bayer Healthcare Ag novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disorders
WO2008021339A2 (fr) 2006-08-15 2008-02-21 Wyeth Pyrrolidine et dérivés associés utiles en tant que modulateurs des récepteurs de la progestérone
BRPI0811581A2 (pt) 2007-05-12 2014-12-09 Bayer Schering Pharma Ag Estimuladores de sgc, ativadores de sgc e combinações para o tratamento de distúrbios urológicos
CA2698332C (fr) * 2007-09-06 2012-08-21 Merck Sharp & Dohme Corp. Derives pyrazole en tant qu'activateurs de la guanylate-cyclase soluble
KR20100063109A (ko) 2007-10-05 2010-06-10 사노피-아벤티스 도이칠란트 게엠베하 통증 치료에서 설포닐-치환된 2-설포닐아미노벤조산 ｎ-페닐아미드의 용도
WO2009068652A1 (fr) 2007-11-30 2009-06-04 Smithkline Beecham Corporation Pyridines 2, 6-disubstituées et pyrimidines 2, 4-disubstituées en tant qu'activateurs de guanylate cyclase soluble
TW200938529A (en) * 2007-12-03 2009-09-16 Smithkline Beecham Corp Compounds
JP5432890B2 (ja) 2008-04-04 2014-03-05 武田薬品工業株式会社 複素環誘導体及びその用途
WO2010015653A1 (fr) * 2008-08-07 2010-02-11 Smithkline Beecham Corporation Dérivés de pyrimidine comme activateurs de guanylate cyclase soluble
WO2010015652A2 (fr) 2008-08-07 2010-02-11 Smithkline Beecham Corporation Composés thiazole utilisés comme activateurs de la guanylate cyclase soluble
EP2373317B1 (fr) 2008-11-25 2016-12-14 Merck Sharp & Dohme Corp. Dérivés de 4-amino-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one ou 4-amino-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one en tant qu'activateurs de la cyclase du guanylat soluble pour le traitement de maladies cardio-vasculaires
SG172841A1 (en) * 2009-01-17 2011-08-29 Bayer Schering Pharma Ag Sgc stimulators of sgc activators in combination with pde5 inhibitors for the treatment of erectile dysfunction
CN102414194A (zh) 2009-02-26 2012-04-11 默沙东公司 可溶性鸟苷酸环化酶激活剂
MY159697A (en) * 2010-02-05 2017-01-13 Adverio Pharma Gmbh Sgc stimulators or sgc activators alone and in combination with pde5 inhibitors for the treatment of cystic fibrosis
WO2011095553A1 (fr) 2010-02-05 2011-08-11 Bayer Schering Pharma Aktiengesellschaft Stimulateurs de sgc ou activateurs de sgc en combinaison avec des inhibiteurs de pde5 pour le traitement du dysfonctionnement érectile
HUE025162T2 (en) * 2010-05-26 2016-04-28 Adverio Pharma Gmbh Use of sGC stimulators, sGC activators alone or in combination with PDE5 inhibitors to treat systemic sclerosis (SSc).
CA2803688A1 (fr) 2010-06-25 2011-12-29 Bayer Intellectual Property Gmbh Utilisation de stimulateurs et d'activateurs de la guanylate-cyclase soluble pour le traitement de la drepanocytose et la conservation de substituts sanguins
WO2012058132A1 (fr) 2010-10-28 2012-05-03 Merck Sharp & Dohme Corp. Activateurs de la guanylate cyclase soluble
US8569339B2 (en) 2011-03-10 2013-10-29 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
WO2013025425A1 (fr) 2011-08-12 2013-02-21 Boehringer Ingelheim International Gmbh Activateurs de guanylate cyclase soluble
EP2594270A3 (fr) 2011-11-18 2013-07-31 BIP Patents Utilisation de stimulateurs de la sGC ou d'activateurs de la sGC, seuls et en combinaison avec des inhibiteurs de PDE5 pour le traitement de la sclérose systémique (Ssc)
PT2892891T (pt) * 2012-09-07 2019-11-05 Boehringer Ingelheim Int Alcoxi pirazoles como ativadores de guanilato ciclase solúvel

Also Published As

Publication number Publication date
WO2014039434A1 (fr) 2014-03-13
HK1210164A1 (en) 2016-04-15
PL2892891T3 (pl) 2020-01-31
TWI586661B (zh) 2017-06-11
US8906904B2 (en) 2014-12-09
SG11201500861QA (en) 2015-04-29
DK2892891T3 (da) 2019-10-14
MD4425B1 (ro) 2016-06-30
JP5970134B2 (ja) 2016-08-17
US20140073629A1 (en) 2014-03-13
AR092869A1 (es) 2015-05-06
NZ703989A (en) 2017-04-28
SG10201510668UA (en) 2016-01-28
KR20150048765A (ko) 2015-05-07
TW201422607A (zh) 2014-06-16
CA2880494C (fr) 2021-09-21
KR101692707B1 (ko) 2017-01-04
MA37891B1 (fr) 2018-05-31
HRP20191755T1 (hr) 2019-12-27
MX2015002807A (es) 2015-05-15
ECSP15012804A (es) 2015-12-31
EA027244B1 (ru) 2017-07-31
EA201500298A1 (ru) 2015-08-31
USRE46886E1 (en) 2018-06-05
CN104619695B (zh) 2018-04-10
CN104619695A (zh) 2015-05-13
CY1122610T1 (el) 2021-03-12
CA2880494A1 (fr) 2014-03-13
PT2892891T (pt) 2019-11-05
ES2748798T3 (es) 2020-03-18
MD20150019A2 (ro) 2015-07-31
MA37891A1 (fr) 2018-01-31
EP2892891B1 (fr) 2019-07-31
AU2013312931A1 (en) 2015-02-05
UA115881C2 (uk) 2018-01-10
GEP20176631B (en) 2017-02-27
BR112015004529A8 (pt) 2019-08-27
IL236987A (en) 2017-02-28
MX338887B (es) 2016-05-04
TN2015000054A1 (en) 2016-06-29
UY35012A (es) 2014-03-31
RS59394B1 (sr) 2019-11-29
PE20151001A1 (es) 2015-07-15
SI2892891T1 (sl) 2019-11-29
HUE046996T2 (hu) 2020-04-28
MD4425C1 (ro) 2017-01-31
BR112015004529A2 (pt) 2017-07-04
PH12015500457B1 (en) 2015-04-20
EP2892891A1 (fr) 2015-07-15
CL2015000255A1 (es) 2015-05-29
BR112015004529B1 (pt) 2022-06-21
CL2015000562A1 (es) 2015-06-12
JP2015527394A (ja) 2015-09-17
PH12015500457A1 (en) 2015-04-20
AU2013312931B2 (en) 2017-06-22
LT2892891T (lt) 2020-01-27

Similar Documents

Publication Publication Date Title
HK1210164A1 (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
IL223259A0 (en) Soluble guanylate cyclase activators
EP2632551A4 (fr) Activateurs de la guanylate cyclase soluble
EP2549875A4 (fr) Activateurs de guanylate cyclase solubles
EP3079700A4 (fr) Activateurs solubles de guanylate cyclase
EP3079701A4 (fr) Activateurs solubles de guanylate cyclase
ME02576B (fr) Inhibiteurs de bace
HK1207376A1 (en) Arylethynyl derivatives
HK1202544A1 (zh) 芳基乙炔基衍生物
SG11201404325VA (en) Pyrimidooxazocine derivatives as mtor - inhibitors
GB201219296D0 (en) Pyrazole derivatives
GB201219289D0 (en) Pyrazole derivatives
GB201218245D0 (en) Pyrazole derivatives
ZA201103204B (en) Phenylpyrazole derivatives